Smart Inhalers Market Size to Reach USD 6.86 Billion by 2035 Driven by AI-Powered Connected Inhalers | SNS Insider

The smart inhalers market is projected to grow through 2035, with the U.S. reaching $2.84B and Europe reaching $2.95B. Growth is attributed to digital health innovation, AI-powered connected inhalers, and rising asthma and COPD prevalence. Overall, the article is a market-forecast update with modest near-term implications.

Analysis

This is less a near-term revenue story than a monetization-of-adherence story. The economic pool is in fewer exacerbations, better refill persistence, and stronger payer evidence, which can modestly improve pricing power and lower churn for respiratory franchises. If connected inhalers become part of standard care, the advantage accrues to incumbents with scale in asthma/COPD and the ability to bundle data, device, and therapy; low-differentiation generic inhaler suppliers would be the most exposed to margin compression.

The second-order issue is reimbursement. Without payer coverage and clinician workflow integration, smart inhalers remain a feature, not a category, and the market can look much larger on slides than in EBITDA. The real catalyst path is 1-3 years: pilot programs converting into formulary preferences, then real-world evidence supporting fewer hospitalizations and lower total cost of care. Falsifier: no meaningful increase in attach rates or documented adherence uplift over the next 2-4 quarters.

My read is the consensus is probably overestimating the immediacy and underestimating the moat effects. The structural winner is not the device layer alone, but the company that can own the longitudinal respiratory dataset and use it to defend share against price competition. That favors large-cap pharma with respiratory exposure over pure-play digital health names, but only once reimbursement becomes visible.

There may be no clean standalone trade today. The cleanest expression is a defensive pair: long the best capitalized respiratory franchise, short a generic-heavy inhaler name, and treat it as a 6-12 month catalyst trade rather than a headline reaction. If evidence of payer adoption or outcomes data does not appear, the thesis should be abandoned rather than averaged into.

Key Decisions for Investors

• No immediate sector-wide trade; keep the theme on watch until reimbursement or outcomes data appears in 1-3 quarters.
• If you want early exposure, initiate a small long GSK / short TEVA pair on weakness, 6-12 month horizon, because connected-device data should favor branded respiratory franchises if adoption proves real.
• Alternative pair: long AZN / short VTRS if respiratory digital adherence starts showing up in earnings commentary; stop out if attach rates and persistence metrics remain flat over two reporting cycles.
• Set alerts for payer coverage, CMS/EMA digital-health guidance, and any disclosed adherence or hospitalization reduction metrics; those are the real catalysts, not market-size projections.